You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesloratadine
Accession NumberDB00967  (APRD00324)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionDesloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
Structure
Thumb
Synonyms
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
Descarboethoxyloratadine
DESLORATADINE
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clarinextablet, film coated5 mg/1oralMerck Sharp & Dohme Corp.2001-12-21Not applicableUs
Clarinexsolution.5 mg/mLoralMerck Sharp & Dohme Corp.2004-09-01Not applicableUs
Clarinextablet, film coated5 mg/1oralRebel Distributors Corp2002-02-08Not applicableUs
Clarinextablet, film coated5 mg/1oralPhysicians Total Care, Inc.2002-06-03Not applicableUs
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOral solution0.5 mg/mlOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOral solution0.5 mg/mlOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOral solution0.5 mg/mlOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOral solution0.5 mg/mlOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOral solution0.5 mg/mlOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOral solution0.5 mg/mlOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOral solution0.5 mg/mlOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOral solution0.5 mg/mlOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet2.5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOrodispersible tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynOral solution0.5 mg/mlOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynFilm-coated tablet5 mgOral useMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DasseltaFilm-coated tablet5 mgOral useKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaFilm-coated tablet5 mgOral useKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaFilm-coated tablet5 mgOral useKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaFilm-coated tablet5 mgOral useKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaFilm-coated tablet5 mgOral useKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaFilm-coated tablet5 mgOral useKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaFilm-coated tablet5 mgOral useKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaFilm-coated tablet5 mgOral useKrka, D.D., Novo Mesto2011-11-28Not applicableEu
Desloratadinesolution.5 mg/mLoralTaro Pharmaceuticals U.S.A., Inc.2015-07-01Not applicableUs
Desloratadinetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2012-07-02Not applicableUs
Desloratadinetablet5 mg/1oralVirtus Pharmaceuticals2012-07-01Not applicableUs
Desloratadinetablet, film coated5 mg/1oralSun Pharmaceutical Industries Limited2010-11-24Not applicableUs
Desloratadinetablet5 mg/1oralAv Kare, Inc.2015-11-24Not applicableUs
Desloratadinetablet, orally disintegrating5 mg/1oralDr. Reddy's Laboratories Limited2013-01-11Not applicableUs
Desloratadinetablet, film coated5 mg/1oralPaddock Laboratories, LLC2014-01-10Not applicableUs
Desloratadinetablet5 mg/1oralbryant ranch prepack2012-07-01Not applicableUs
Desloratadinetablet5 mg/1oralAv Pak2015-11-25Not applicableUs
Desloratadinetablet, orally disintegrating2.5 mg/1oralDr. Reddy's Laboratories Limited2013-01-11Not applicableUs
Desloratadinetablet5 mg/1oralSandoz Inc2013-07-01Not applicableUs
Desloratadinetablet, film coated5 mg/1oralLupin Pharmaceuticals, Inc.2013-02-14Not applicableUs
Desloratadinetablet5 mg/1oralAv Pak2013-10-09Not applicableUs
Desloratadinetablet5 mg/1oralBelcher Pharmaceuticals,LLC2012-05-15Not applicableUs
Desloratadinetablet5 mg/1oralAv Kare, Inc.2012-07-05Not applicableUs
Desloratadinetablet5 mg/1oralVirtus Pharmaceuticals2015-06-12Not applicableUs
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisFilm-coated tablet5 mgOral useActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmFilm-coated tablet5 mgOral useRatiopharm Gmb H2012-01-13Not applicableEu
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aeriussyrup0.5 mgoralBayer Inc Consumer CareNot applicableNot applicableCanada
Aeriustablet5 mgoralBayer Inc Consumer Care2002-01-10Not applicableCanada
Aerius Kidssyrup0.5 mgoralBayer Inc Consumer Care2005-03-21Not applicableCanada
Allergy Control Desloratadinetablet5 mgoralPharmascience IncNot applicableNot applicableCanada
Allernix Multi Symptomtablet5 mgoralTeva Canada Limited2012-01-31Not applicableCanada
Desloratadine Allergy Controltablet5 mgoralPharmel Inc2014-03-10Not applicableCanada
Desloratadine Allergy Controltablet5 mgoralPharmascience Inc2009-12-24Not applicableCanada
Desloratadine Tabletstablet5 mgoralApotex Inc2010-05-27Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
ClaramaxNot Available
NeoClaritynNot Available
Brand mixtures
NameLabellerIngredients
Aerius Dual Action 12 HourBayer Inc Consumer Care
Aerius Dual Action 24 HourBayer Inc Consumer Care
Clarinex-D 12 HourMerck Sharp & Dohme Corp.
SaltsNot Available
Categories
UNIIFVF865388R
CAS number100643-71-8
WeightAverage: 310.821
Monoisotopic: 310.123676325
Chemical FormulaC19H19ClN2
InChI KeyInChIKey=JAUOIFJMECXRGI-UHFFFAOYSA-N
InChI
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
IUPAC Name
13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3(8),4,6,12,14-hexaene
SMILES
ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzocycloheptapyridines. These are aromatic compounds containing a benzene ring and a pyridine ring fused to a seven membered carbocycle.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzocycloheptapyridines
Sub ClassNot Available
Direct ParentBenzocycloheptapyridines
Alternative Parents
Substituents
  • Benzocycloheptapyridine
  • Chlorobenzene
  • Benzenoid
  • Pyridine
  • Piperidine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
PharmacodynamicsDesloratadine is a long-acting second-generation H1-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergies. Desloratadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Desloratadine does not enter the brain from the blood and, therefore, does not cause drowsiness.
Mechanism of actionLike other H1-blockers, Desloratadine competes with free histamine for binding at H1-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding82-87%
MetabolismNot Available
Route of eliminationDesloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. Approximately 87% of a 14C-desloratadine dose was equally recovered in urine and feces.
Half life50 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.965
Caco-2 permeable-0.5121
P-glycoprotein substrateSubstrate0.7758
P-glycoprotein inhibitor IInhibitor0.6694
P-glycoprotein inhibitor IINon-inhibitor0.794
Renal organic cation transporterInhibitor0.6979
CYP450 2C9 substrateNon-substrate0.8554
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5634
CYP450 1A2 substrateInhibitor0.7786
CYP450 2C9 inhibitorNon-inhibitor0.738
CYP450 2D6 inhibitorNon-inhibitor0.7377
CYP450 2C19 inhibitorNon-inhibitor0.7837
CYP450 3A4 inhibitorNon-inhibitor0.8332
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6083
Ames testNon AMES toxic0.6514
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0370 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7382
hERG inhibition (predictor II)Inhibitor0.8016
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering corp
  • Doctor reddys laboratories ltd
  • Schering plough corp
  • Orchid healthcare
Packagers
Dosage forms
FormRouteStrength
Tabletoral5 mg
Tablet (extended-release)oral
Tablet (immediate and extended release)oral
Syruporal0.5 mg
Solutionoral.5 mg/mL
Tablet, film coatedoral5 mg/1
Tablet, extended releaseoral
Film-coated tabletOral use5 mg
Tabletoral5 mg/1
Tablet, orally disintegratingoral2.5 mg/1
Tablet, orally disintegratingoral5 mg/1
Oral solutionOral use0.5 mg/ml
Orodispersible tabletOral use2.5 mg
Orodispersible tabletOral use5 mg
Prices
Unit descriptionCostUnit
Clarinex Reditabs 30 5 mg Dispersible Tablet Box150.0USD box
Clarinex Reditabs 30 2.5 mg Dispersible Tablet Box147.14USD box
Clarinex-D 24 Hour 5-240 mg 24 Hour tablet5.0USD tablet
Clarinex-d 24 hour tablet4.8USD tablet
Clarinex 5 mg tablet4.57USD tablet
Clarinex-D 12 Hour 2.5-120 mg 12 Hour tablet3.2USD tablet
Clarinex-d 12 hour tablet3.08USD tablet
Clarinex 0.5 mg/ml Syrup0.48USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2267136 No2000-11-282018-02-06Canada
CA2294352 No2008-05-062018-07-01Canada
US5178878 No1993-01-122010-01-12Us
US5607697 Yes1995-12-072015-12-07Us
US6100274 Yes2000-01-072020-01-07Us
US6514520 Yes1998-12-012018-12-01Us
US6709676 No2001-02-182021-02-18Us
US6979463 No2002-03-282022-03-28Us
US7405223 Yes2000-01-072020-01-07Us
US7618649 Yes2001-06-192021-06-19Us
US7820199 Yes2002-09-282022-09-28Us
US8187630 No2000-12-192020-12-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00395 mg/mLALOGPS
logP3.48ALOGPS
logP3.97ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)9.73ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.92 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity101.04 m3·mol-1ChemAxon
Polarizability34.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Zoltan Toth, “Processes for preparation of polymorphic forms of desloratadine.” U.S. Patent US20040242619, issued December 02, 2004.

US20040242619
General References
  1. Mann RD, Pearce GL, Dunn N, Shakir S: Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000 Apr 29;320(7243):1184-6. [PubMed:10784544 ]
  2. Glass DJ, Harper AS: Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. BMC Fam Pract. 2003 Aug 13;4:10. Epub 2003 Aug 13. [PubMed:12917016 ]
  3. See S: Desloratadine for allergic rhinitis. Am Fam Physician. 2003 Nov 15;68(10):2015-6. [PubMed:14655812 ]
  4. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052 ]
  5. Bachert C: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. [PubMed:19539095 ]
  6. DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8(5):271-83. [PubMed:17902729 ]
  7. Bachert C, Maurer M: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010;30(2):109-22. doi: 10.2165/11530930-000000000-00000. [PubMed:20067329 ]
  8. Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22. [PubMed:12642846 ]
External Links
ATC CodesR06AX27
AHFS Codes
  • 04:08.00
PDB EntriesNot Available
FDA labelDownload (200 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with 1,10-Phenanthroline.
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Desloratadine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Desloratadine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desloratadine.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Desloratadine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Desloratadine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Desloratadine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Desloratadine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Desloratadine.
AclidiniumAclidinium may increase the anticholinergic activities of Desloratadine.
AclidiniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Aclidinium.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Desloratadine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Desloratadine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desloratadine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Desloratadine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desloratadine.
AlfentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Desloratadine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desloratadine.
AmbenoniumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Ambenonium.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Desloratadine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desloratadine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Desloratadine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desloratadine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desloratadine.
AmoxapineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Desloratadine.
AmphetamineAmphetamine may decrease the sedative activities of Desloratadine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Desloratadine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Desloratadine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desloratadine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Desloratadine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Desloratadine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Desloratadine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Desloratadine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Desloratadine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Desloratadine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Desloratadine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Desloratadine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Desloratadine.
AzelastineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desloratadine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Desloratadine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Desloratadine.
BenactyzineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Desloratadine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Desloratadine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desloratadine.
BenzphetamineBenzphetamine may decrease the sedative activities of Desloratadine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Desloratadine.
Benzylpenicilloyl PolylysineDesloratadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Desloratadine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Desloratadine.
BezitramideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Desloratadine.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Desloratadine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Desloratadine.
Botulinum Toxin Type ADesloratadine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BDesloratadine may increase the anticholinergic activities of Botulinum Toxin Type B.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desloratadine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Desloratadine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
BrimonidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desloratadine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Desloratadine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desloratadine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Desloratadine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desloratadine.
BuprenorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Desloratadine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desloratadine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Desloratadine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Desloratadine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Desloratadine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Desloratadine.
ButorphanolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Desloratadine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Desloratadine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Desloratadine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Desloratadine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Desloratadine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desloratadine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desloratadine.
CarfentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Desloratadine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desloratadine.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Desloratadine.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Desloratadine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desloratadine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desloratadine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desloratadine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Desloratadine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desloratadine.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Desloratadine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenoxamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Desloratadine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Desloratadine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desloratadine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desloratadine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Desloratadine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desloratadine.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Desloratadine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Desloratadine.
CimetropiumDesloratadine may increase the anticholinergic activities of Cimetropium.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desloratadine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Desloratadine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Desloratadine.
CitalopramThe risk or severity of adverse effects can be increased when Desloratadine is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Desloratadine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Desloratadine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Desloratadine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Desloratadine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Desloratadine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Desloratadine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Desloratadine.
ClomipramineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Desloratadine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Desloratadine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Desloratadine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desloratadine.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Desloratadine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Desloratadine.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Desloratadine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desloratadine.
CodeineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Codeine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Desloratadine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Desloratadine.
CoumaphosThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Coumaphos.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Desloratadine.
CyclizineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desloratadine.
CyclopentolateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclopentolate.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Desloratadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desloratadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Desloratadine.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Desloratadine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Desloratadine.
DantroleneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Desloratadine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desloratadine.
DapoxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Desloratadine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Desloratadine.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Desloratadine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Desloratadine.
DecamethoniumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Demecarium.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Desloratadine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Desloratadine.
DesipramineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Desipramine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Desloratadine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Desloratadine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desloratadine.
DexetimideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dexetimide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desloratadine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Desloratadine.
DextromoramideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Desloratadine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Desloratadine.
DichlorvosThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Desloratadine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Desloratadine.
DifenoxinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Desloratadine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Desloratadine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Desloratadine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Desloratadine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desloratadine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Desloratadine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Desloratadine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Desloratadine.
DonepezilThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Donepezil.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Desloratadine.
DoxepinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Desloratadine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
DoxylamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Desloratadine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
DronabinolDesloratadine may increase the tachycardic activities of Dronabinol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Desloratadine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Desloratadine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desloratadine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Desloratadine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Desloratadine.
EchothiophateThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Echothiophate.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Desloratadine.
EdrophoniumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Edrophonium.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desloratadine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Desloratadine.
EluxadolineDesloratadine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Desloratadine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Desloratadine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Desloratadine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Desloratadine.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Desloratadine.
EscitalopramThe risk or severity of adverse effects can be increased when Desloratadine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Desloratadine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Desloratadine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Desloratadine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Desloratadine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desloratadine.
EthanolDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Desloratadine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desloratadine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Desloratadine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Desloratadine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desloratadine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desloratadine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desloratadine.
EthylmorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Desloratadine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Desloratadine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Desloratadine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Desloratadine.
EtoperidoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Desloratadine.
EtorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etorphine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Desloratadine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Desloratadine.
EzogabineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Desloratadine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Desloratadine.
FenfluramineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fentanyl.
FenthionThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Fenthion.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Desloratadine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Desloratadine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Desloratadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Desloratadine.
FlibanserinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desloratadine.
FlunarizineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desloratadine.
FluoxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desloratadine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desloratadine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desloratadine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Desloratadine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Desloratadine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Desloratadine.
FluvoxamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Desloratadine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desloratadine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Desloratadine is combined with gabapentin enacarbil.
GalantamineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Desloratadine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Desloratadine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Desloratadine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Desloratadine.
Ginkgo bilobaThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Desloratadine is combined with Glucagon recombinant.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Desloratadine.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Desloratadine.
GlycopyrroniumDesloratadine may increase the anticholinergic activities of Glycopyrronium.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Desloratadine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Desloratadine.
GuanfacineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Desloratadine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Desloratadine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desloratadine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Desloratadine.
HeroinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hexamethonium.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desloratadine.
HomatropineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desloratadine.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Desloratadine.
HydrocodoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Desloratadine.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Desloratadine.
HydromorphoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Desloratadine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
HydroxyzineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Desloratadine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Desloratadine.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Desloratadine.
IloperidoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Desloratadine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Desloratadine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desloratadine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Desloratadine.
IndalpineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Indalpine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Desloratadine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Desloratadine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Desloratadine.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Desloratadine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Desloratadine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desloratadine.
IsoflurophateThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Desloratadine.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Desloratadine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desloratadine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Desloratadine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Desloratadine.
KetobemidoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Desloratadine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Desloratadine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Desloratadine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desloratadine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Desloratadine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Desloratadine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Desloratadine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Desloratadine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Desloratadine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Desloratadine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Desloratadine.
LevocabastineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Desloratadine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Desloratadine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Desloratadine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Desloratadine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Desloratadine.
LofentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Desloratadine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Desloratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desloratadine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Desloratadine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desloratadine.
Lu AA21004The risk or severity of adverse effects can be increased when Desloratadine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desloratadine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Magnesium Sulfate.
MalathionThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Malathion.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Desloratadine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desloratadine.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Desloratadine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desloratadine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Desloratadine.
MefloquineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Desloratadine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Desloratadine.
MemantineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Memantine.
MephentermineMephentermine may decrease the sedative activities of Desloratadine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desloratadine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desloratadine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desloratadine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desloratadine.
MethadoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may decrease the sedative activities of Desloratadine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Desloratadine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desloratadine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Desloratadine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desloratadine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Desloratadine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Desloratadine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Desloratadine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desloratadine.
MethsuximideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Desloratadine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desloratadine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Desloratadine.
MetixeneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Desloratadine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Desloratadine.
MetyrosineDesloratadine may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Desloratadine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Desloratadine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Desloratadine.
MilnacipranThe risk or severity of adverse effects can be increased when Desloratadine is combined with Milnacipran.
MinaprineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
MirabegronThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mirabegron.
MirtazapineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desloratadine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Desloratadine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Desloratadine.
MorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Desloratadine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Desloratadine is combined with N-butylscopolammonium bromide.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
NabiloneDesloratadine may increase the tachycardic activities of Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Desloratadine.
NalbuphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Desloratadine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Desloratadine.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Desloratadine.
NeostigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Neostigmine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Desloratadine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Desloratadine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Desloratadine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Desloratadine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desloratadine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Desloratadine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Desloratadine.
NormethadoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desloratadine.
NVA237The risk or severity of adverse effects can be increased when Desloratadine is combined with NVA237.
OlanzapineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desloratadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Desloratadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Desloratadine.
OpiumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Opium.
OrphenadrineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Desloratadine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Desloratadine.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Desloratadine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desloratadine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Desloratadine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desloratadine.
OxybutyninThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Desloratadine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Desloratadine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Desloratadine.
PancuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pancuronium.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Desloratadine.
ParaldehydeDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Desloratadine.
ParoxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Desloratadine.
PentazocineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desloratadine.
PentoliniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pentolinium.
PerampanelThe risk or severity of adverse effects can be increased when Desloratadine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Desloratadine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desloratadine.
PethidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pethidine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Desloratadine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desloratadine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Desloratadine.
PhenterminePhentermine may decrease the sedative activities of Desloratadine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Desloratadine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Desloratadine.
PhysostigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Physostigmine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Desloratadine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Desloratadine.
PipecuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipecuronium.
PipotiazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Desloratadine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Desloratadine.
PizotifenThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pizotifen.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Desloratadine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Desloratadine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Desloratadine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Desloratadine.
Potassium ChlorideDesloratadine may increase the ulcerogenic activities of Potassium Chloride.
PramipexoleDesloratadine may increase the sedative activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Desloratadine.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desloratadine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Desloratadine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Desloratadine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Desloratadine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Desloratadine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Desloratadine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desloratadine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Desloratadine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Desloratadine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Desloratadine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desloratadine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Desloratadine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Desloratadine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Desloratadine.
PromethazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Desloratadine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desloratadine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Desloratadine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Desloratadine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Desloratadine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desloratadine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Desloratadine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Desloratadine.
PyridostigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Pyridostigmine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Desloratadine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Desloratadine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Desloratadine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Desloratadine.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Desloratadine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Desloratadine.
RamelteonThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ramelteon.
RamosetronDesloratadine may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Desloratadine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Desloratadine.
RemifentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desloratadine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Desloratadine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Desloratadine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Desloratadine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Desloratadine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Desloratadine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Desloratadine.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Desloratadine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Desloratadine.
RivastigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Rivastigmine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Desloratadine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Desloratadine.
RopiniroleDesloratadine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desloratadine.
RotigotineDesloratadine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Desloratadine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desloratadine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Desloratadine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Desloratadine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desloratadine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Scopolamine butylbromide.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desloratadine.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Desloratadine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Desloratadine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Desloratadine.
SertralineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desloratadine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Desloratadine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Desloratadine.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Desloratadine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Desloratadine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Desloratadine.
SolifenacinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Solifenacin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Desloratadine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Desloratadine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Desloratadine.
StiripentolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Desloratadine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desloratadine.
SuvorexantThe risk or severity of adverse effects can be increased when Desloratadine is combined with Suvorexant.
TacrineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Desloratadine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Desloratadine.
TapentadolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Desloratadine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Desloratadine.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Desloratadine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desloratadine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Desloratadine.
TetrabenazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desloratadine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desloratadine.
ThalidomideDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Desloratadine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desloratadine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Desloratadine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Desloratadine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Desloratadine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desloratadine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desloratadine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Desloratadine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Desloratadine.
TimololThe serum concentration of Timolol can be increased when it is combined with Desloratadine.
TiotropiumDesloratadine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Desloratadine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Desloratadine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desloratadine.
TolterodineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tolterodine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Desloratadine.
TopiramateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Desloratadine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Desloratadine.
TramadolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tramadol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Desloratadine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desloratadine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Desloratadine.
TrazodoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desloratadine.
TrichlorfonThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Desloratadine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desloratadine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desloratadine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Desloratadine.
TrimethaphanThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trimethaphan.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desloratadine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desloratadine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Desloratadine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Desloratadine.
TubocurarineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tubocurarine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Desloratadine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Desloratadine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Umeclidinium.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Desloratadine.
VecuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vecuronium.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Desloratadine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Desloratadine.
VigabatrinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Desloratadine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Desloratadine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Desloratadine.
VortioxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Desloratadine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desloratadine.
ZiconotideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Desloratadine.
ZimelidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Desloratadine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Desloratadine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desloratadine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desloratadine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Desloratadine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Desloratadine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desloratadine.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Wu RL, Anthes JC, Kreutner W, Harris AG, West RE Jr: Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor. Int Arch Allergy Immunol. 2004 Dec;135(4):313-8. Epub 2004 Nov 24. [PubMed:15564772 ]
  2. Cieslewicz G, Gondorowicz K, Grzelewska-Rzymowska I, Rozniecki J: [Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction]. Pneumonol Alergol Pol. 1995;63(5-6):281-5. [PubMed:7581058 ]
  3. Letari O, Miozzo A, Folco G, Belloni PA, Sala A, Rovati GE, Nicosia S: Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol. 1994 Feb 15;266(3):219-27. [PubMed:8174605 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052 ]
  6. DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8(5):271-83. [PubMed:17902729 ]
  7. Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22. [PubMed:12642846 ]
  8. Dhanya NB, Thasleem Z, Rai R, Srinivas CR: Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):361-3. [PubMed:18797058 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. [PubMed:11454724 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 03:40